|
KMID : 1103920130190020165
|
|
Korean Journal of Hepatology
2013 Volume.19 No. 2 p.165 ~ p.172
|
|
|
Efficacy and safety of entecavir plus carnitine complex (GODEXⓡ) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
|
|
Jun Dae-Won
Kim Byung-Ik
Cho Yong-Kyun
Kim Hong-Ju
Kwon Young-Oh
Park Soo-Young
Han Sang-Young
Baek Yang-Hyun
Jung Yong-Jin
Kim Hwi-Young
Kim Won
Heo Jeong
Woo Hyun-Young
Hwang Seong-Gyu
Rim Kyu-Sung
Choi Jong-Young
Bae Si-Hyun
Lee Young-Sang
Lim Young-Suck
Cheong Jae-Youn
Cho Sung-Won
Lee Byung-Seok
Kim Seok-Hyun
Sohn Joo-Hyun
Kim Tae-Yeob
Paik Yong-Han
Kim Ja-Kyung
Lee Kwan-Sik
|
|
|
Abstract
|
|
|
Background/Aims: Carnitine and vitamin complex (Godexⓡ) is widely used in patients with chronic liver disease who show elevated liver enzyme in South Korea. The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients.
Methods: 130 treatment-naive patients with CHB were enrolled from 13 sites. The patients were randomly selected to the entecavir and the complex of entecavir and carnitine. The primary endpoint of the study is ALT normalization level after 12 months.
Results: Among the 130 patients, 119 patients completed the study treatment. The ALT normalization at 3 months was 58.9% for the monotherapy and 95.2% for the combination therapy (P<0.0001). ALT normalization rate at 12 months was 85.7% for the monotherapy and 100% for the combination group (P=0.0019). The rate of less than HBV DNA 300 copies/mL at 12 months was not statistically significant (P=0.5318) 75.9% for the monotherapy, 70.7% for the combination and it was. Quantification of HBsAg level was not different from the monotherapy to combination at 12 months. Changes of ELISPOT value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to monotreatment.
Conclusions: ALT normalization rate was higher in carnitine complex combination group than entecavir group in CHB. Combination group was faster than entecavir mono-treatment group on ALT normalization rate. HBV DNA normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment.
|
|
|
KEYWORD
|
|
|
Hepatitis B, Carnitine, Entecavir
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|